Wren C, Campbell R W
Br Heart J. 1987 Feb;57(2):171-5. doi: 10.1136/hrt.57.2.171.
Flecainide acetate was administered intravenously and orally to 12 consecutive children, aged 1-15 years, presenting with arrhythmias that were life threatening or resistant to conventional medical treatment. Three children had arrhythmias related to Wolff-Parkinson-White syndrome, four had concealed accessory pathways, two had His bundle tachycardia, and three had ventricular tachycardia. Of seven patients who were given flecainide intravenously, four returned to sinus rhythm and in a fifth successful rate control of His bundle tachycardia was achieved. All 12 patients were given the drug orally: in nine it was successful in preventing recurrence of arrhythmia, in one satisfactory rate control was achieved, and in two it was withdrawn because it produced more frequent attacks of tachycardia. No other adverse effects occurred. The efficacy and low toxicity of treatment in this study suggests that flecainide acetate may have an important role in the management of selected paediatric arrhythmias.
对12名年龄在1至15岁、患有危及生命或对传统药物治疗耐药的心律失常的连续儿童,静脉注射和口服醋酸氟卡尼。3名儿童的心律失常与预激综合征有关,4名有隐匿性附加通路,2名有希氏束心动过速,3名有室性心动过速。在7名接受静脉注射氟卡尼的患者中,4名恢复窦性心律,第5名成功控制了希氏束心动过速的心率。所有12名患者均口服该药:9名成功预防心律失常复发,1名实现了满意的心率控制,2名因导致心动过速发作更频繁而停药。未出现其他不良反应。本研究中治疗的有效性和低毒性表明,醋酸氟卡尼在某些小儿心律失常的管理中可能具有重要作用。